Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B GOTTLIEB

Showing results (301-310 of 523) with videos related to

Pageof 53
Sort By:
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Dermatology (Basel, Switzerland)|May 22, 2019
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM)Nicole Salame, Josefina Torres, Jeena Sandhu, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|May 16, 2007
Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann, Alice B Gottlieb, George S Deepe, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.
Journal of Clinical Immunology|December 29, 2023
IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 HaploinsufficiencyConor Gruber, Angelica Lee, Sofija Buta, et al.
Journal of the American Academy of Dermatology|June 23, 2009
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonistsAdam Asarch, Alice B Gottlieb, Jin Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease managementLluís Puig, Siew Eng Choon, Alice B Gottlieb, et al.
Pageof 53

Showing results (301-310 of 523) with videos related to

Sort By:
Pageof 53
Journal of the American Academy of Dermatology|April 3, 2018
Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trialKim A Papp, Joseph F Merola, Alice B Gottlieb, et al.
Lancet (London, England)|June 13, 2018
Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyAtul Deodhar, Alice B Gottlieb, Wolf-Henning Boehncke, et al.
Dermatology (Basel, Switzerland)|May 22, 2019
Patient-Reported Outcome Measures for Pediatric Psoriasis: A Systematic Review and Critical Appraisal from International Dermatology Outcome Measures (IDEOM)Nicole Salame, Josefina Torres, Jeena Sandhu, et al.
Journal of the American Academy of Dermatology|September 25, 2004
Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trialAlice B Gottlieb, Robert Evans, Shu Li, et al.
The Journal of Investigative Dermatology. Symposium Proceedings|May 16, 2007
Structural-functional relationships of TNF-alpha antagonists: next stepsFrank J Dann, Alice B Gottlieb, George S Deepe, et al.
Journal of Drugs in Dermatology : JDD|August 30, 2013
Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label studyAlice B Gottlieb, Robert T Matheson, Alan Menter, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 20, 2012
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasisR G Langley, K Papp, A B Gottlieb, et al.
Journal of Clinical Immunology|December 29, 2023
IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 HaploinsufficiencyConor Gruber, Angelica Lee, Sofija Buta, et al.
Journal of the American Academy of Dermatology|June 23, 2009
Lichen planus-like eruptions: an emerging side effect of tumor necrosis factor-alpha antagonistsAdam Asarch, Alice B Gottlieb, Jin Lee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 6, 2023
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease managementLluís Puig, Siew Eng Choon, Alice B Gottlieb, et al.
Pageof 53